ERBB2 and breast carcinoma: Furthermore, multiple studies have demonstrated that the breast cancer with sPR-positive and HER-2-negative phenotype has the same clinicopathological characteristics as triple-negative subtype and is also not sensitive to endocrine therapy (11, 16–19).